The EUA allowed Evusheld to be given as pre-exposure prophylaxis for individuals age 12 and older who are moderately to severely immunocompromised, or for whom vaccination is not recommended due to a history of severe allergic reactions to vaccines. It was not intended as a substitute for vaccination. Evusheld is given as an injection into the muscle.
Never Miss a Beat!
Subscribe to Our HealthBeat Newsletter!
Thank you for subscribing!
You can now select the specific newsletters you'd like to receive.
You are already subscribed.
Subscribe to more newsletters in our email preference center.
Sorry, an error occurred. Please try again later.
Get Healthy Tips Sent to Your Phone!
What Is Evusheld?
Evusheld, made by AstraZeneca, is a combination of tixagevimab and cilgavimab. It was a type of medicine called a monoclonal antibody, which is offered to some immunocompromised patients to prevent serious illness from COVID-19.
The COVID-19 virus changes over time. The FDA revoked its authorization of Evusheld because it is no longer effective against most current COVID-19 variants. Because it is no longer authorized, health care providers in the U.S., including UPMC, can no longer offer Evusheld to patients.
The company that makes Evusheld is creating an updated version of the medication that may work better against current and future COVID-19 variants. This updated medicine is in early testing. It is unclear when it will be available for patients.
Who Is Eligible For Evusheld?
Patients can no longer receive Evusheld in the United States.
Prior to January 2023, certain people with specific illnesses and medical situations were eligible to receive Evusheld. People who are immunocompromised may be eligible for other types of COVID-19 treatments.
How Can I Receive Evusheld?
The FDA has revoked its authorization of this medication, and it cannot be administered in the United States.
If you have questions or concerns about COVID-19, contact your provider. For now, it’s is important to continue following infection prevention measures such as:
- Wearing a mask
- Staying home if you are ill
- Washing your hands frequently
- Covering your coughs and sneezes
If you become sick, get tested for COVID-19. If you test positive, talk to your provider as soon as possible to see if you are eligible for certain treatments, including Paxlovid, which is a pill, or remdesivir, an injection that can treat COVID-19 infections.
If you have a weakened immune system, remind your provider that you are at high risk for severe COVID-19 infection.
Editor's Note: This video was originally published on , and was last reviewed on .
Connect with UPMC
Headquartered in Pittsburgh, UPMC is a world-renowned health care provider and insurer. We operate 40 hospitals and 800 doctors’ offices and outpatient centers, with locations throughout Pennsylvania, Maryland, New York, West Virginia, and internationally. We employ 4,900 physicians, and we are leaders in clinical care, groundbreaking research, and treatment breakthroughs. U.S. News & World Report consistently ranks UPMC Presbyterian Shadyside as one of the nation’s best hospitals in many specialties and ranks UPMC Children’s Hospital of Pittsburgh on its Honor Roll of America’s Best Children’s Hospitals. We are dedicated to providing Life Changing Medicine to our communities.
Disclaimer: At UPMC HealthBeat, we strive to provide the most up-to-date facts in our stories when we publish them. We also make updates to our content as information changes. However, education about COVID-19 can shift quickly based on new data, emerging variants, or other factors. The information in this story was accurate as of its publish date. We also encourage you to visit other reliable websites for updated information, including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and your state and local governments.
In December 2021, the U.S. Food and Drug Administration (FDA) issued emergency use authorization (EUA) for a new anti-COVID-19 medication, the AstraZeneca product called Evusheld™.
This monoclonal antibody was designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination.
As of January 2023, Evusheld is no longer authorized for use by the FDA and may not be administered in the U.S. UPMC has ceased administering this medication accordingly.
Evusheld is no longer effective against the most COVID-19 variants circulating in the community.